Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower CIN3+ associated with HPV16/18 (age 15 to 26 years) (high certainty).
1 finding from 1 review
Intervention not reported
AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention probably leads to lower AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type (age 15 to 26 years) (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Any AIS irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CIN2+ associated with HPV16/18. · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower CIN2+ associated with HPV16/18. (high certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
AIS associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention probably leads to lower AIS associated with HPV16/18 (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention showed no clear difference in any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN3+ irrespective of HPV type (high certainty).
1 finding from 1 review
Intervention not reported
Any AIS irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention probably leads to lower any AIS irrespective of HPV type (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of diphtheria, tetanus, pertussis, Haemophilus influenzae type b (Hib) (not measured) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐severe local reaction10 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The intervention probably leads to lower non‐severe local reaction10 (moderate certainty).
1 finding from 1 review
Intervention not reported
Fever14 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
It is very uncertain whether the intervention changes fever14 (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of diphtheria, tetanus, pertussis, Haemophilus influenzae type b (Hib) (not measured) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP combination vaccine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
2a. Adequate immune response (seroprotection) against diphtheria (surrogate outcome) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP combination vaccine
The intervention showed no clear difference in 2a. Adequate immune response (seroprotection) against diphtheria… (moderate certainty).
1 finding from 1 review